Clinical Trials | June 02, 2026
Eli Lilly drug slashes lung cancer recurrence risk by 83% in landmark phase 3 trial
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
The approval is supported by results from the Phase 3 SWOG 1826 trial
Aims to bridge transparency gaps in fertility care, with focus on successful patient outcomes, placing healthy live birth outcomes at the centre of treatment journeys
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
The technology enables clinicians to assess brain tissue and microvascular reperfusion directly in the angiography suite, potentially improving stroke treatment decisions and patient outcomes
The conference highlighted research suggesting that deuterium levels may influence key biological processes
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually
Subscribe To Our Newsletter & Stay Updated
